GlassScriptPhysician profile
Karen Hernandez
NPI 1427284413
$4,514.21
in general payments reported to CMS, 2019-2025
29 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $232 · 2023: $402 · 2024: $1,663 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,716 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.61 |
| Education | $288.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $936.48 | 2022-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $558.49 | 2024-2025 | Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $398.83 | 2022-2025 | Kisqali, Piqray |
| Lilly USA, LLC | $370.81 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $370.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $266.53 | 2023-2025 | Keytruda, Lynparza |
| Tersera Therapeutics LLC | $250.86 | 2024-2025 | Zoladex |
| Genentech USA, INC. | $212.75 | 2021-2025 | Itovebi |
| Puma Biotechnology, INC. | $149.52 | 2023-2025 | |
| Genentech, INC. | $132.27 | 2025 | Itovebi |
| Seagen INC. | $119.31 | 2021 | |
| Gilead Sciences, INC. | $104.48 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $92.18 | 2023-2025 | Erleada, Talvey, Rybrevant |
| Alexion Pharmaceuticals, INC. | $84.89 | 2024-2025 | Ultomiris |
| Myriad Genetic Laboratories, INC. | $65.11 | 2024-2025 | Myrisk |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $49.74 | 2022-2024 | |
| Caris Mpi, INC. | $46.74 | 2025 | Mi Cancer Seek |
| Tactile Systems Technology INC | $44.68 | 2024 | Flexitouch Plus, Entre Plus |
| Abbvie INC. | $44.62 | 2022 | |
| Incyte Corporation | $27.91 | 2025 | Jakafi |
| Eisai INC. | $26.11 | 2024 | |
| Sobi, INC | $23.61 | 2025 | |
| Tempus Ai, INC | $23.32 | 2024 | Xt Cdx |
| Servier Pharmaceuticals LLC | $23.08 | 2024 | |
| Amgen INC. | $19.58 | 2023 | Evenity, Prolia |
| Adaptive Biotechnologies Corporation | $19.56 | 2024 | Clonoseq |
| Genmab U.S., INC. | $18.11 | 2024 | Epkinly |
| Stemline Therapeutics INC. | $17.70 | 2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $16.29 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.